Lumosa Therapeutics Co., Ltd.
Taipei Exchange 6535.TWO
Lumosa Therapeutics Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 731.15
Lumosa Therapeutics Co., Ltd. Price to Sales Ratio (P/S) is 731.15 on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
Lumosa Therapeutics Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 1,070.23 on October 28, 2024, which is 46.38% above the current Price to Sales Ratio (P/S).
-
Lumosa Therapeutics Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 478.51 on December 16, 2024, which is -34.55% below the current Price to Sales Ratio (P/S).
-
Lumosa Therapeutics Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 762.65.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
Taipei Exchange: 6535.TWO
| CEO | Li Fang Pan |
| IPO Date | July 16, 2015 |
| Location | |
| Headquarters | No. 3-2, Park Street |
| Employees | 47 |
| Sector | Health Care |
| Industries | |
Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email